Novartis, India’s Biological E. Team Up To Develop New Typhoid Vaccines
This article was originally published in PharmAsia News
Executive Summary
After GSK partnered with Biological E. earlier this year to develop a six-in-one pediatric vaccine, Novartis said it will out-license two typhoid vaccines to the Indian vaccines company, one of which has cleared proof-of-concept.